Fat Transfer to the Face: The Fastest-Growing Procedure Is Not a Filler

What happened

The American Society of Plastic Surgeons released its 2025 procedure statistics this week. Cosmetic surgery volume rose 7 percent in a year, and the single procedure that grew fastest was facial fat grafting, up 39 percent. Forehead lifts, neck lifts, eyelid surgery and facelifts all rose with it. In the same report, 82 percent of surgeons said they had received consultation requests related to GLP-1 weight-loss medication, although the society is careful to say the data do not prove that the drugs caused the growth in any one procedure.

I read the number differently from most of the coverage. Fat transfer to the face is not a new procedure, and it did not get 39 percent better in a year. What changed is that many more faces have lost volume quickly, and fat is being sold to them as the natural, permanent alternative to filler. Half of that sentence is true.

The common misconception

The misconception is that fat is a filler made from you. It is not a filler at all. It is a graft.

A filler is a product: the volume you inject is the volume you get, and it fades on a schedule. A graft is living tissue moved from one place to another. It has to survive the move, find a blood supply in its new home, and then it lives there for the rest of your life, doing what fat does. That difference explains everything patients find confusing about fat transfer: why the early result is bigger than the final one, why the surgeon cannot promise a volume, and why what you weigh in five years matters.

The clinical reality

About half of the fat survives, sometimes more, and nobody can tell you in advance which. The most honest numbers come from studies that measured the face objectively rather than by photograph. A meta-analysis of 27 studies and 1,011 patients put the pooled retention at 47 percent, with individual studies ranging from 26 to 83 percent, and found that second-round grafting tends to retain better than the first. A pooled review of 515 patients measured with three-dimensional scanning found the same spread, 21 to 82 percent. A single-center series that scanned 22 faces at 3, 6 and 12 months found about 44 percent surviving at one year, with most of the loss in the first three months. So the working figure I give patients is around half, and in a good recipient site it can be well above that. Surgeons who quote you one number are quoting their own average. The range is the truth.

Red Light Therapy: What the Viral Studies Actually Say

The face you see at two weeks is not your result. Early fullness is graft plus swelling plus fat that will not make it. By three months most of the loss has happened; by six months you are looking at what you keep. I judge a fat transfer at six months and I ask patients to do the same. This is the same rule I wrote about for facelift swelling: the third month lies, in both directions.

Surviving fat is your fat, and it follows your weight. This is the point that separates fat from filler and the one that decides timing. A graft that took is living fat tissue in your cheek. If you gain ten kilograms, it gains with you; if you lose ten, it shrinks. That is why I do not graft a face that is still losing weight. There is something close to comic about asking fat to settle into a cheek while the rest of the body is busy burning it, and it is the same reason I do not lift one. The volume I place today would be a different volume by spring.

GLP-1 medication is an open question, and I treat it as one. A scoping review published in June 2026 asked directly whether these drugs sabotage fat grafts. The biology gives reasons for concern: the drugs increase fat breakdown, push fat cells toward a type that burns rather than stores, and may interfere with the new blood vessels a graft depends on in its first weeks. The same review found no clinical study, none, that has actually measured graft survival in patients on these medications. So the honest position is: mechanism says be careful, data says we do not know. My practical rule is that I want the weight stable, and I want to know exactly what the patient is taking before I harvest fat. What to do with the medication around surgery is a conversation with the prescribing doctor, not a decision I make alone.

Additives are not a reason to choose a clinic. Fat mixed with platelet-rich plasma, stromal vascular fraction or nanofat is marketed as fat that survives better. A 2026 meta-analysis of stromal vascular fraction reported around 17 percent better retention, but the studies disagreed with each other so strongly that the authors called for proper trials before anyone relies on the number. A 2022 systematic review of all additives rated 20 of 27 studies as weak and concluded it remains unclear whether any of them help. I use careful harvesting, gentle processing and small-volume placement, and I use nanofat for skin quality, not for volume. I do not sell survival.

Fillers Will Not Fix Ozempic Face: An Honest Look at Weight Loss, Timing and the Facelift Question

Fat replaces volume. It does not lift. This is where the 39 percent worries me. A face that has deflated after weight loss has usually done two things: lost volume and dropped. Fat corrects the first. Only a facelift corrects the second. Grafting fat into a face that needs lifting produces a heavier face that still sags, and I see the results of that in second opinions. In my own facelift patients fat is the second half of the same operation, placed after the deep tissues are repositioned, as in the deep plane case I have published on this site.

The practical takeaway for patients

Send unedited photographs in daylight, front and both sides, and a photograph of yourself at your previous weight if you have lost a lot. Tell me how much you lost, over what period, whether the weight has been stable for a few months, and what medication you take. Those four facts decide whether fat is right for you now, later, or not at all.

Ask any surgeon two questions. First: what percentage of the fat do you expect to survive in my case, and what is the plan if less does? A second, smaller session is a normal part of fat transfer, not a failure, and it should be discussed before the first one. Second: does my face need volume, lifting, or both? A surgeon who only offers fat will answer the first question well and the second one badly.

If you want a reversible trial of what more volume would look like, a filler is a legitimate way to find out. Fat is the answer once you know.

Honest limits

The survival figures come from pooled studies with very different methods, and from patients who were not on weight-loss medication. The GLP-1 question has no clinical answer yet, and I will update this article when it does.

Buccal Fat Removal: Who It Suits, and What the Cheek Does With Age

For some faces filler remains the better tool: small corrections, patients who want reversibility, patients who are not ready for a procedure that involves harvesting. And for faces that have dropped, no volume of fat replaces the lift.

If you are wondering whether your face needs volume, a lift, or both, send unedited photographs to +90 544 772 0772. The surgical team reviews them the same day and tells you which it is.

Dr. Mustafa Aydınol is a plastic, reconstructive and aesthetic surgeon in Istanbul and a member of ISAPS.

Sources

American Society of Plastic Surgeons. 2025 Procedural Statistics Report, press release, 1 September 2026. Link
Lv Q, Li X, Qi Y, Gu Y, Liu Z, Ma GE. Volume retention after facial fat grafting and relevant factors: a systematic review and meta-analysis, 27 studies, 1,011 patients, pooled retention 47 percent. Aesthetic Plast Surg, 2021. DOI
Wang GH, Zhao JF, Xue HY, Li D. Facial aesthetic fat graft retention rates after filtration, centrifugation, or sedimentation processing techniques measured using three-dimensional surface imaging devices, pooled data of 515 patients. Chin Med J, 2019. DOI
Zhu M, Xie Y, Zhu Y, Chai G, Li Q. A novel noninvasive three-dimensional volumetric analysis for fat-graft survival in facial recontouring, 22 patients, 12-month follow-up. J Plast Reconstr Aesthet Surg, 2016. DOI
Chalhoub X, Ng ZY. Do GLP-1 receptor agonists sabotage fat grafts? A scoping review of GLP-1 receptor agonist effects on adipocyte biology and implications for autologous fat transfer. Aesthet Surg J, 2026. DOI
Jefri ZE, Alashjaee RH, Almarri AK, et al. Stromal vascular fraction-assisted fat grafting: a systematic review and meta-analysis, 18 studies, 893 patients. Aesthetic Plast Surg, 2026. DOI
Schipper JAM, Vriend L, Tuin AJ, et al. Supplementation of facial fat grafting to increase volume retention: a systematic review of 27 studies. Aesthet Surg J, 2022. DOI